TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04998188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen
Description: Patients will be treated with a single injection of collagen (2 ml) in the knee joint affected by osteoarthritis

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline solution)
Description: Patients will be treated with a single injections of saline solution (2 ml) in the knee joint affected by osteoarthritis
Study: NCT06371079

Intervention type: DEVICE
Intervention: phakic intraocular lens implantation traditional
Description: patients with refractive errors undergo surgical implantation of a lens inside the eye (implantable collamer lens or ICL) to correct these refractive errors. The procedure is done with help of use of both cohesive and dispersive OVD

Intervention type: DEVICE
Intervention: phakic intraocular lens implantation reduced OVD
Description: patients with refractive errors undergo surgical implantation of a lens inside the eye (implantable collamer lens or ICL) to correct these refractive errors. The procedure is done with help of use of only cohesive OVD without using dispersive OVD.
Study: NCT05393765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yönetebilirim
Description: Yönetebilirim is an interactive web-based program developed to improve the self-management skills of individuals with MS by supporting self-regulation under the leadership of nurses.
Study: NCT06218030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-methylfolate
Description: Oral administration of L-methylfolate 15 mg per day for 8 weeks. The study drug will be given in addition to the standard of care (SOC) for GAD.
Study: NCT06306573

Intervention type: DEVICE
Intervention: CardioMEMS HF System
Description: The CardioMEMS HF System provides pulmonary artery (PA) hemodynamic data to monitor and manage HF subjects. The CardioMEMS HF System measures PA pressure which clinicians use to initiate or modify HF treatment.

Intervention type: DEVICE
Intervention: CardioMEMS HF System
Description: The CardioMEMS HF System provides pulmonary artery (PA) hemodynamic data to monitor and manage HF subjects. The CardioMEMS HF System measures PA pressure which clinicians use to initiate or modify HF treatment.
Study: NCT05165173

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NanoD4CKD
Description: Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of nanoparticles of D3 and instructed to consume it in the morning with a meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MicroD4CKD
Description: Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of microparticles of D3 and instructed to consume it in the morning with a meal.
Study: NCT05629117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Diabetes Text Messaging (DB-TEXT) combined with Peer Support Education
Description: Patients who are assigned to the DB-TEXT+PSE group will receive personalized short text message services twice weekly at approximately noon on Monday and Thursday for three months (12 weeks). Furthermore, they will receive the peer support education weekly from the peer supporter by telephone during three months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Diabetes Text Messaging (DB-TEXT)
Description: Personalized Diabetes Text Messaging (DB-TEXT)
Study: NCT06496711

Intervention type: OTHER
Group type: OTHER
Intervention: Cancer Patients; Institutions and their employees in the treatment and/or counseling of cancer patients
Description: The study population will be surveyed at 3 yearly measurement time points by means of questionnaires and interviews on attitudes, barrier and support factors for participation in exercise therapy.
Study: NCT06566430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP My Way intervention
Description: Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, 6, 9, and 12 for those choosing the oral or ring formulations of PrEP. If the participant chooses to use injections, she will communicate with the peers to arrange for kit delivery at Months 1, 3, 5, 7, 9, 11, and 12. All deliveries will be made via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 12 and as needed (e.g., treatment for positive tests).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP My Way intervention without STI testing
Description: Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. This kit will not contain STI testing. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, 6, 9, and 12 for those choosing the oral or ring formulations of PrEP. If the participant chooses to use injections, she will communicate with the peers to arrange for kit delivery at Months 1, 3, 5, 7, 9, 11, and 12. All deliveries will be made via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 12 and as needed (e.g., treatment for positive tests).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced standard of care
Description: These participants will receive PrEP (choice of oral, ring, or injection formulation), STI testing, and family planning at the clinic, as requested.
Study: NCT06563440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital app and information system
Description: A custom digital app and information system that consists of four modules: (1) ID module - captures child's demographic and biometric data and builds a printable QR-code; (2) Assay module - captures point of care test image, interprets, and transmits results to the central ministry of health data center; (3) Education module - stores and plays back short educational videos for pre- and post-screening counseling; (4) SCD e-Passport module - entry and display of child's salient clinical information.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital app and information system
Description: A custom digital app and information system that consists of four modules: (1) ID module - captures child's demographic and biometric data and builds a printable QR-code; (2) Assay module - captures point of care test image, interprets, and transmits results to the central ministry of health data center; (3) Education module - stores and plays back short educational videos for pre- and post-screening counseling; (4) SCD e-Passport module - entry and display of child's salient clinical information.
Study: NCT06564272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KC1036
Description: For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036. For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036. For patients weighing 70 kg or more, administer 60 mg QD of KC1036. 4 weeks as a cycle.
Study: NCT06568315

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Concurrent multiple micronutrient and calcium supplementation
Description: Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement providing 30 mg elemental iron and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate together every morning from enrollment through the end of pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Separate multiple micronutrient and calcium supplementation
Description: Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement (MMS) providing 30 mg elemental iron every morning and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate every evening from enrollment through the end of pregnancy
Study: NCT05517005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hype Bites Supplement
Description: The ingredients of the vitamin supplement are:~Chocolate liquor Sugar Cocoa butter Vanilla extract Vitamin B12 (as methylcobalamin) Tapioca Gum arabic Coloring (radish, apple, black currant) Carnauba Wax
Study: NCT04296071

Intervention type: OTHER
Intervention: Research study
Description: Blood and tracheal aspirates will be collected

Intervention type: OTHER
Intervention: Research study
Description: Blood and tracheal aspirates will be collected
Study: NCT05104450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: Intervention Arm: Usual Care plus a lifestyle behavior change intervention aimed at improving eating habits and increasing physical activity. The lifestyle behavior change intervention encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.
Study: NCT06381401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 0.25%
Description: superficial cervical plexus block using 10 ml of bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 0.125%
Description: superficial cervical plexus block using 10 ml of bupivacaine 0.125%
Study: NCT06248671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40mg
Description: Each tablet will be taken once daily for 84 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each tablet will be taken once daily for 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg
Description: Each tablet will be taken once daily for 84 days.
Study: NCT06547814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard implementation webinar and online training
Description: The one-hour webinar (either live or pre-recorded) will include updated information about the COVID-19 virus, variant nomenclature, vaccine eligibility, mechanisms of action, and outcomes. The 30-minute online training addresses how to communicate about COVID-19 vaccinations, presents a 5-step process for initiating conversations, includes example verbiage about how to address specific concerns, and has example videos that show how to implement the 5-step process with vaccine hesitant patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual facilitation
Description: This intervention involves a 30-minute virtual facilitation site visit and at least 8, 30-minute virtual facilitator coaching sessions. The virtual site visit over Zoom will establish the personnel and workflows at each pharmacy and allow the facilitator to establish rapport. Weekly Zoom calls will allow the virtual facilitator to work with a participant to review overall implementation challenges associated with approaching patients, delivering the intervention, and documenting results. Lastly, either the facilitator or the participant can request and schedule a Zoom call to go over any pressing implementation issue in need of rapid attention (e.g., technical difficulties with the website).
Study: NCT05388136

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional follow up schedule with imaging
Description: Frequent of follow up visit and imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deintensified follow up schedule without imaging
Description: Less intense follow up visit without imaging
Study: NCT04843332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Support
Description: For those in the experimental group, a community health worker will provide health education and support as described in the Community Health Worker Intervention arm.
Study: NCT06414265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement
Description: The SATURN TS TMVR System will be implanted through a transcatheter approach in patients with symptomatic mitral regurgitation.
Study: NCT06156046

Intervention type: DIAGNOSTIC_TEST
Intervention: skin prick test
Description: Skin prick test for bee venom

Intervention type: DIAGNOSTIC_TEST
Intervention: skin prick test
Description: Skin prick test for bee venom

Intervention type: DIAGNOSTIC_TEST
Intervention: skin prick test
Description: Skin prick test for bee venom

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: IgE/G and T cell tolerance studies

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: IgE/G and T cell tolerance studies

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: IgE/G and T cell tolerance studies
Study: NCT06565689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK012
Description: YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
Study: NCT05302414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Board game-based learning
Description: The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through a board game-based teaching approach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation-based learning
Description: The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through a simulation-based teaching approach.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lecture-based learning
Description: The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through an interactive lecture-based approach.
Study: NCT05264818

Intervention type: PROCEDURE
Intervention: Glycocheck
Description: Assessment of the sublingual microvascularization

Intervention type: PROCEDURE
Intervention: Glycocheck
Description: Assessment of the sublingual microvascularization

Intervention type: PROCEDURE
Intervention: Ophthalmological examinations
Description: Description :~Measurement of best corrected distance visual acuity with ETDRS (Early Treatment Diabetic Retinopathy Study) Measurement of intraocular pressure by aplanation and forced air tonometer Central corneal thickness measurement with OCT (Optical Coherence Tomography) Non-mydriatic retinophotography Humphrey 24-2 visual field OCT-RNFL (Optical Coherence Tomography - retinal nerve fiber layer)

Intervention type: PROCEDURE
Intervention: Ophthalmological examinations
Description: Description :~Measurement of best corrected distance visual acuity with ETDRS (Early Treatment Diabetic Retinopathy Study) Measurement of intraocular pressure by aplanation and forced air tonometer Central corneal thickness measurement with OCT (Optical Coherence Tomography) Non-mydriatic retinophotography Humphrey 24-2 visual field OCT-RNFL (Optical Coherence Tomography - retinal nerve fiber layer)
Study: NCT05726318

Intervention type: DRUG
Group type: OTHER
Intervention: Antibiotics
Description: Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoaxole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoaxole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days
Study: NCT05008419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative discourse treatment
Description: The protocol will incorporate elements from prior treatment studies that showed some promise: 1) hierarchical training, 2) variety of discourse stimuli, 3) development of skills and strategies for discourse processing, 4) structured training prompts, 5) meta-cognitive and meta-linguistic strategies, and 6) integration of learning principles. Novel treatment elements will include: 1) targeting both story content and story organization, 2) use of a discourse model to guide treatment, and 3) functional communication training. Treatment will be delivered twice a week over 8 weeks. There will be four treatment phases: education, story organization, story content, and integration of story organization and content.
Study: NCT05996523

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGN-2009
Description: PRGN-2009 5x10\^11 viral particles (VP) subcutaneously (SC) approximately two weeks apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg intravenously (IV) concurrently with the first vaccine dose
Study: NCT05935410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DM Social Needs
Description: 6-monthly sessions of telephone delivered, manualized education and skills training on diabetes management, and problem solving and resolution of social needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Diabetes education materials in accordance with recommendations from the American Diabetes Association (ADA) will be mailed monthly.
Study: NCT05405751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
Description: Patients enrolled in the study and accessing the HIV consultation will start treatment with BIKTARVY on the day of enrollment. Medication will be provided by the sponsor and dispensed through the pharmacy service. The drug will be delivered to the patient with a delegated person outside the hospital environment or it will be the patient himself who picks up the medication.
Study: NCT06301438

Intervention type: DRUG
Intervention: dalpiciclib
Description: dalpiciclib oral day 1-21, every 28 days
Study: NCT05692232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure biofeedback guided DCFM strength training
Description: A pressure biofeedback guided DCFM strength training was carried out according to the Jull protocol. Keeping the participant's cervical spine in a neutral position and ensuring a stabilizer pressure biofeedback unit placed beneath the cervical lordosis. The pressure sensor was inflated at 20mm Hg. The participants were asked to nod their heads slowly. As the DCFM is activated, the cervical lordosis gently flattens, and the pressure sensor measures an increase in pressure. The activation score is the maximum pressure that can maintain for 10 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: A manual therapy, including a slow, sustained elongation of muscles with a holding period of 7-10 seconds and a superficial oscillatory mobilization (grade-I) with 1-2 oscillations per second for 30 seconds per session was performed on the DCFM and at the cervical spine (C0-C5), respectively. The participants were asked to lie supine and prone while delivering stretching and mobilization, respectively.
Study: NCT06303141

Intervention type: OTHER
Group type: OTHER
Intervention: Closed Chain exercises
Description: Open eyes and closed eyes across arm (3 sets x 60 sec) Lateral step down (3 sets x 6-12 reps) Semi-Squat Exercise (3sets x 6-12 reps) Thera-band isometric (3 sets x 10 -15sec each)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: Neuromuscular Training Exercise:~* Single Leg Raise (3 sec x 30sec each)~* Ankle eversion/inversion (3 sets x 25 reps)~* Double Hopping in place then out of place (3 sets 30 sec)~* Reach with feet (3 sets x 30-60 sec each)~* Reach with hands (3 sets x 30-60 sec each)~* Wobble board Exercise (3sets x 30-60sec each

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with Movement
Description: Joint mobilization with movement (by Mulligan) refers to manual therapy techniques that are used to modulate pain and treat joint dysfunctions that limit the range of motion (ROM).~(3 sets x 6 oscillation/glide each)
Study: NCT05339633

Intervention type: DRUG
Group type: OTHER
Intervention: [14C]-D-0502
Description: Drug: \[14C\]-D-0502 and D-0502
Study: NCT06058598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: 6-months supervised exercise training + 6 months unsupervised exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Counselling
Description: 12-months of lifestyle counselling
Study: NCT06373978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 50mg every 8hours as needed for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 50mg every 8hours as needed for pain

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acetaminophen
Description: 1000mg every 8hours as needed for pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000mg every 8hours as needed for pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000mg every 8hours as needed for pain
Study: NCT05377866

Intervention type: OTHER
Intervention: Remote proctoring using HoloLens
Description: Assess Microsoft HoloLens as an interactive communication device in remote proctoring, and enhancement of teamwork in complex CTO procedures.
Study: NCT05121688

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: A Tele-face-to-face multimodal physical therapy program based on health education, respiratory exercises, physical training exercises, aerobic exercises and functional mobility.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: A Tele-face-to-face multimodal physical therapy program based on health education, respiratory exercises, physical training exercises, aerobic exercises and functional mobility.